

TABLE OF CONTENTS

| | |
|--|-----------|
| 0. Executive Summary | 15 |
| 1. Basics of Drug Delivery to the Central Nervous System | 17 |
| Introduction..... | 17 |
| Historical evolution of drug delivery for CNS disorders | 17 |
| Neuroanatomical and neurophysiological basis of drug delivery | 18 |
| The cerebrospinal fluid | 18 |
| The extracellular space in the brain | 19 |
| Neurotransmitters | 19 |
| Neuropharmacology relevant to drug delivery | 21 |
| Introduction to neuropharmacology | 21 |
| Pharmacokinetics | 21 |
| <i>Absorption and distribution of drugs</i> | <i>21</i> |
| <i>Drug metabolism and elimination</i> | <i>22</i> |
| Pharmacodynamics | 22 |
| <i>Receptors.....</i> | <i>22</i> |
| Sites of drug action in the CNS | 22 |
| <i>Receptors coupled to guanine nucleotide binding proteins</i> | <i>23</i> |
| <i>Acetylcholine receptor channels</i> | <i>23</i> |
| <i>Dopamine receptors</i> | <i>23</i> |
| <i>GABA receptor channels.....</i> | <i>24</i> |
| <i>Glutamate receptor channels</i> | <i>24</i> |
| <i>Non-competitive NMDA antagonists</i> | <i>24</i> |
| <i>Serotonin receptors</i> | <i>25</i> |
| <i>G-protein coupled receptors</i> | <i>25</i> |
| In vivo study of drug action in the CNS in human patients | 25 |
| <i>Electroencephalography</i> | <i>25</i> |
| <i>Brain imaging</i> | <i>26</i> |
| Chronopharmacology as applied to the CNS | 26 |
| 2. Blood Brain Barrier | 29 |
| Introduction..... | 29 |
| Features of the blood-brain barrier relevant to CNS drug delivery | 29 |
| The neurovascular unit | 29 |
| Functions of the BBB | 30 |
| <i>BBB as an anatomical as well as physiological barrier</i> | <i>30</i> |
| <i>BBB as a biochemical barrier</i> | <i>31</i> |
| Role of shear stress on development of BBB | 31 |
| Genomics of BBB | 32 |
| Proteomics of BBB..... | 32 |
| Other neural barriers | 33 |
| Blood-cerebrospinal fluid barrier | 33 |
| Blood nerve barrier | 33 |
| Blood-retinal barrier | 34 |
| Blood-labyrinth barrier..... | 34 |
| Passage of substances across the blood-brain barrier | 34 |
| Transporters localized in the BBB | 34 |
| <i>Glucose transporter</i> | <i>35</i> |
| <i>Amino acid transporters</i> | <i>36</i> |
| <i>Ionic transporter</i> | <i>36</i> |
| <i>Efflux transport systems</i> | <i>36</i> |
| BBB-specific enzymes | 37 |
| Receptor-mediated transcytosis | 38 |
| Lysophosphatidic acid-mediated increase in BBB permeability | 38 |
| Folate transport system | 39 |
| Molecular biology of the BBB | 39 |
| Transport of peptides and proteins across the BBB | 39 |
| <i>Passage of leptin across the BBB.....</i> | <i>39</i> |
| <i>Passage of cytokines across the BBB</i> | <i>40</i> |
| <i>Passage of hormones across the BBB.....</i> | <i>40</i> |
| <i>Passage of enzymes across the BBB</i> | <i>41</i> |
| <i>Drugs that cross the BBB by binding to plasma proteins.....</i> | <i>41</i> |
| Current concepts of the permeability of the BBB | 41 |
| Factors that increase the permeability of the BBB | 42 |
| BBB disruption as an adverse effect of pharmaceuticals | 42 |
| BBB disruption as adverse effect of vaccines for CNS disorders | 43 |
| Effect of CNS disorders on BBB | 43 |

| | |
|---|-----------|
| Autoimmune disorders | 44 |
| Brain tumors | 44 |
| <i>Primary brain tumors</i> | 44 |
| <i>Cerebral metastases</i> | 44 |
| Central nervous system injuries | 45 |
| Cerebrovascular disease | 45 |
| Epilepsy | 46 |
| Infections..... | 46 |
| Mitochondrial encephalopathies | 47 |
| Multiple sclerosis..... | 47 |
| Neurodegenerative disorders..... | 47 |
| Testing permeability of the BBB..... | 48 |
| In vitro models of BBB..... | 49 |
| In vivo study of BBB..... | 50 |
| <i>Brain imaging</i> | 50 |
| In silico prediction of BBB | 50 |
| Relevance of the BBB penetration to pharmacological action..... | 52 |
| <i>BBB penetration and CNS drug screening</i> | 52 |
| <i>CERENSESM</i> | 52 |
| Transthyretin monomer as a marker of blood-CSF barrier disruption | 53 |
| Evaluation of BBB permeability by brain imaging..... | 53 |
| Biomarkers of disruption of blood-brain barrier | 53 |
| Future directions for research on the BBB | 54 |
| Use of neural stem cells to construct the blood brain barrier..... | 55 |
| Strategies to cross the BBB..... | 55 |

3. Methods of Drug Delivery to the CNS **57**

| | |
|--|-----------|
| Introduction..... | 57 |
| Routes of drug delivery to the brain | 58 |
| Delivery of drugs to the brain via the nasal route..... | 58 |
| <i>Passage of viruses to the brain via the nasal route</i> | 59 |
| <i>Potential and limitations of nasal drug delivery to the brain</i> | 59 |
| <i>Nasal delivery of insulin-like growth factor-I</i> | 60 |
| <i>Nasal delivery of midazolam</i> | 60 |
| <i>Nasal delivery of hypocretin</i> | 60 |
| <i>Nasal administration of IFN beta-1b</i> | 61 |
| <i>Nasal administration of erythropoietin</i> | 61 |
| <i>Nasal delivery of thyrotropin-releasing hormone by nanoconstructs</i> | 61 |
| <i>Nasal delivery of neuroprotective drugs for stroke</i> | 62 |
| Transdermal drug delivery for neurological disorders | 62 |
| Drug delivery to the brain via inner ear..... | 62 |
| Invasive neurosurgical approaches..... | 63 |
| <i>Intraarterial drug delivery to the brain</i> | 63 |
| <i>Direct injection into the CNS substance or CNS lesions</i> | 64 |
| <i>Targeted delivery of biologicals to the spinal cord by microinjection</i> | 64 |
| <i>Intraventricular injection of drugs</i> | 64 |
| <i>Intrathecal drug delivery</i> | 65 |
| <i>Retrograde delivery to the brain via the epidural venous system</i> | 66 |
| <i>Devices for drug delivery to the CNS</i> | 67 |
| Strategies for drug delivery to the CNS across the BBB | 68 |
| Increasing the permeability (opening) of the BBB..... | 68 |
| <i>Osmotic opening of the BBB</i> | 68 |
| <i>Focal disruption of BBB by ultrasound</i> | 69 |
| <i>Chemical opening of the BBB</i> | 69 |
| <i>Cerebral vasodilatation to open the BBB</i> | 69 |
| <i>Modulation of vascular permeability by laser irradiation</i> | 70 |
| <i>Use of nitric oxide donors to open the BBB</i> | 70 |
| <i>Manipulation of the sphingosine 1-phosphate receptor system</i> | 70 |
| Pharmacological strategies to facilitate transport across the BBB | 71 |
| <i>2B-TransTM technology</i> | 71 |
| <i>ABC efflux transporters and penetration of the BBB</i> | 71 |
| <i>Carrier-mediated drug delivery across the BBB</i> | 72 |
| <i>G-Technology®</i> | 73 |
| <i>Glycosylation Independent Lysosomal Targeting</i> | 73 |
| <i>Inhibition of P-glycoprotein to enhance drug delivery across the BBB</i> | 73 |
| <i>Modification of the drug to enhance its lipid solubility</i> | 74 |
| <i>Monoclonal antibody fusion proteins</i> | 75 |
| <i>Neuroimmunophilins</i> | 75 |
| <i>Peptide-mediated transport across the BBB</i> | 75 |
| <i>Prodrug bioconversion strategies and their CNS selectivity</i> | 77 |
| <i>Role of the transferrin-receptor system in CNS drug delivery</i> | 78 |

| | |
|---|------------|
| <i>Transport of small molecules across the BBB</i> | 78 |
| <i>Transport across the BBB by short chain oligoglycerolipids</i> | 78 |
| <i>Transvascular delivery across the BBB</i> | 78 |
| <i>Trojan horse approach</i> | 79 |
| <i>Use of receptor-mediated transcytosis to cross the BBB</i> | 80 |
| Cell-based drug delivery to the CNS | 81 |
| <i>Activated T lymphocytes</i> | 81 |
| <i>Microglial cells</i> | 82 |
| <i>Neural stem cells</i> | 82 |
| Drug delivery to the CNS by using novel formulations | 82 |
| <i>Crystalline formulations</i> | 82 |
| <i>Liposomes</i> | 82 |
| <i>Monoclonal antibodies</i> | 84 |
| <i>Microspheres</i> | 84 |
| <i>Microbeads</i> | 85 |
| Brain-targeted chemical delivery systems | 85 |
| Nanotechnology-based drug delivery to CNS | 86 |
| Nanoparticles for drug delivery across the BBB | 86 |
| <i>Penetration of BBB by nanoparticles coated with polysorbate 80</i> | 87 |
| <i>NanoDel™ technology for crossing the BBB</i> | 87 |
| <i>Masking BBB-limiting characteristics by nanotechnology</i> | 87 |
| <i>Peptide-nanoparticle conjugates for crossing the BBB</i> | 87 |
| <i>Nanovesicles for transport across BBB</i> | 88 |
| Nanotechnology-based devices and implants for CNS | 88 |
| Biochip implants for drug delivery to the CNS | 88 |
| Controlled-release microchip | 88 |
| Retinal implant chip | 89 |
| Convection-enhanced delivery to the CNS | 89 |
| Systemic administration of drugs for CNS effects | 90 |
| Sustained and controlled release drug delivery to the CNS | 90 |
| <i>Fast dissolving oral selegiline</i> | 92 |
| Choice of the route of systemic delivery for effect on the CNS disorders | 92 |
| Methods of delivery of biopharmaceuticals to the CNS | 93 |
| Delivery of biopharmaceuticals across the BBB | 93 |
| Methods of delivery of peptides for CNS disorders | 93 |
| <i>Challenges for delivery of peptides across the BBB</i> | 94 |
| <i>Transnasal administration of neuropeptides</i> | 94 |
| <i>Direct delivery of neuropeptides into the brain</i> | 94 |
| <i>Alteration of properties of the BBB for delivery of peptides</i> | 95 |
| <i>Molecular manipulations of peptides to facilitate transport into CNS</i> | 95 |
| <i>CNS delivery of peptides via conjugation to biological carriers</i> | 95 |
| <i>Delivery of conopeptides to the brain</i> | 96 |
| Delivery of neurotrophic factors to the nervous system | 96 |
| <i>Systemic administration of NTFs</i> | 98 |
| <i>Delivery systems to facilitate crossing of the BBB by NTFs</i> | 99 |
| <i>Use of microspheres for delivery of neurotrophic factors</i> | 99 |
| <i>Intracerebroventricular injection</i> | 99 |
| <i>Direct application of NTFs to the CNS</i> | 100 |
| <i>Intrathecal administration</i> | 101 |
| <i>Implants for delivery of neurotrophic factors</i> | 101 |
| <i>Use of neurotrophic factor mimics</i> | 101 |
| Use of microorganisms for therapeutic entry into the brain | 103 |
| Bacteriophages as CNS therapeutics | 103 |
| Intracellular drug delivery in the brain | 103 |
| Local factors in the brain affecting drug action | 103 |
| Methods for testing drug delivery to the CNS | 104 |
| Animal models for testing drug delivery | 104 |
| Screening for drug-P-gp interaction at BBB | 104 |
| 4. Delivery of Cell, Gene and Antisense Therapies to the CNS | 105 |
| Introduction | 105 |
| Cell therapy of neurological disorders | 105 |
| Methods for delivering cell therapies in CNS disorders | 105 |
| <i>Encapsulated cells</i> | 106 |
| <i>Genetically modified stem cells for metachromatic leukodystrophy</i> | 107 |
| <i>CNS neotissue implant</i> | 107 |
| <i>CNS delivery of cells by catheters</i> | 107 |
| <i>Subarachnoid delivery of stem cells</i> | 108 |
| <i>Intravascular administration</i> | 108 |
| Gene therapy techniques for the nervous system | 109 |
| Introduction | 109 |

| | |
|---|------------|
| Methods of gene transfer to the nervous system | 110 |
| AAV vector mediated gene therapy for neurogenetic disorders..... | 111 |
| Ideal vector for gene therapy of neurological disorders | 111 |
| Promoters of gene transfer..... | 111 |
| Routes of delivery of genes to the nervous system | 112 |
| <i>Direct injection into CNS</i> | 112 |
| <i>Introduction of the genes into cerebral circulation</i> | 113 |
| <i>Introduction of genes into cerebrospinal fluid</i> | 113 |
| <i>Intravenous administration of vectors</i> | 113 |
| <i>Delivery of gene therapy to the peripheral nervous system</i> | 114 |
| Cell-mediated gene therapy of neurological disorders | 114 |
| <i>Neuronal cells</i> | 114 |
| <i>Neural stem cells and progenitor cells</i> | 114 |
| <i>Astrocytes</i> | 114 |
| <i>Cerebral endothelial cells</i> | 115 |
| <i>Implantation of genetically modified encapsulated cells into the brain</i> | 115 |
| <i>Genetically modified bone marrow cells</i> | 115 |
| Nanoparticles as non-viral vectors for CNS gene therapy | 116 |
| Applications of gene therapy for neurological disorders | 116 |
| Companies involved in cell/gene therapy of neurological disorders | 117 |
| Antisense therapy of CNS disorders | 118 |
| Delivery of antisense oligonucleotides to the CNS..... | 119 |
| Delivery of oligonucleotides cross the BBB | 120 |
| Cellular delivery systems for oligonucleotides | 120 |
| High-flow microinfusion into the brain parenchyma | 121 |
| Systemic administration of peptide nucleic acids | 121 |
| Introduction of antisense compounds into the CSF Pathways | 121 |
| Intrathecal administration of antisense compounds | 122 |
| Intracerebroventricular administration of antisense oligonucleotides..... | 122 |
| Nanoparticle-based delivery of antisense therapy to the CNS..... | 123 |
| Methods of delivery of ribozymes | 123 |
| Delivery aspects of RNAi therapy of CNS disorders | 124 |
| Delivery of siRNA to the CNS | 124 |
| Future drug delivery strategies applicable to the CNS | 124 |
| | |
| 5. Drug Delivery for Treatment of Neurological Disorders | 127 |
| Introduction..... | 127 |
| Parkinson's disease | 127 |
| Drug delivery systems for Parkinson's disease | 128 |
| <i>Methods of delivery of levodopa in PD</i> | 130 |
| <i>Duodenal levodopa infusion</i> | 130 |
| <i>Sublingual apomorphine</i> | 130 |
| <i>Transdermal drug delivery for PD</i> | 130 |
| <i>Transdermal dopamine agonists for PD</i> | 131 |
| <i>Transdermal administration of other drugs for PD</i> | 132 |
| <i>Intracerebral administration of GDNF</i> | 132 |
| Cell therapy for PD | 133 |
| <i>Human dopaminergic neurons for PD</i> | 134 |
| <i>Graft survival-enhancing drugs</i> | 134 |
| <i>Xenografting porcine fetal neurons</i> | 135 |
| <i>Encapsulated cells for PD</i> | 135 |
| <i>Stem cells for PD</i> | 136 |
| <i>Engineered stem cells for drug delivery to the brain in PD</i> | 137 |
| <i>Human retinal pigment epithelium cells for PD</i> | 137 |
| <i>Delivery of cells for PD</i> | 138 |
| Gene therapy for Parkinson disease..... | 138 |
| <i>Rationale</i> | 138 |
| <i>Techniques of gene therapy for PD</i> | 139 |
| <i>Prospects of gene therapy for PD</i> | 143 |
| <i>Companies developing gene therapy for PD</i> | 143 |
| RNAi therapy of Parkinson's disease | 144 |
| Alzheimer disease | 144 |
| Drug delivery for Alzheimer disease | 144 |
| Blood-brain partitioning of an AMPA receptor modulator..... | 145 |
| Clearing amyloid through the BBB..... | 145 |
| Delivery of the passive antibody directly to the brain | 146 |
| Delivery of thyrotropin-releasing hormone analogs by molecular packaging..... | 146 |
| Intranasal delivery of nerve growth factor to the brain..... | 146 |
| Nanoparticle-based drug delivery for Alzheimer's disease | 147 |
| Perispinal etanercept | 147 |
| Slow release implant of an AChE inhibitor | 148 |

| | |
|---|------------|
| Transdermal drug delivery in Alzheimer's disease..... | 148 |
| Trojan-horse approach to prevent build-up of A β aggregates..... | 148 |
| Cell and gene therapy for Alzheimer disease..... | 149 |
| <i>NGF gene therapy</i> | 149 |
| <i>Neprilysin gene therapy</i> | 150 |
| RNAi therapy of Alzheimer's disease..... | 150 |
| Huntington's disease | 151 |
| Treatment of HD..... | 151 |
| Gene therapy of HD..... | 151 |
| <i>Encapsulated genetically engineered cellular implants</i> | 151 |
| <i>Viral vector mediated administration of neurotrophic factors</i> | 152 |
| <i>RNAi therapeutics for the treatment of HD</i> | 152 |
| Amyotrophic lateral sclerosis | 152 |
| Treatment of ALS..... | 152 |
| Drug delivery in ALS..... | 153 |
| Gene and antisense therapy of amyotrophic lateral sclerosis..... | 154 |
| <i>Neurotrophic factor gene therapies of ALS</i> | 154 |
| <i>Antisense therapy of ALS</i> | 155 |
| <i>RNAi therapy of amyotrophic lateral sclerosis</i> | 155 |
| Drug delivery for CNS involvement in Hunter syndrome | 156 |
| Cerebrovascular disease | 156 |
| Treatment of stroke..... | 157 |
| Drug delivery in stroke..... | 157 |
| <i>Intraarterial administration of tissue plasminogen activator in stroke</i> | 158 |
| Drug delivery for prevention of restenosis of carotid arteries..... | 159 |
| <i>Modified NO donors</i> | 159 |
| <i>In-stent restenosis</i> | 160 |
| <i>Targeted local anti-restenotic drug delivery</i> | 160 |
| <i>Catheter-based drug delivery for restenosis</i> | 161 |
| <i>Stents for prevention of restenosis</i> | 161 |
| <i>Drug-eluting stents</i> | 162 |
| <i>Antisense approach to prevent restenosis</i> | 162 |
| Drug-eluting stents for the treatment of intracranial atherosclerosis..... | 163 |
| Tissues transplants for stroke..... | 163 |
| <i>Transplant of encapsulated tissue secreting neurotrophic factors</i> | 163 |
| Cell therapy for stroke..... | 163 |
| <i>Stem cell transplant into the brain</i> | 164 |
| <i>Immortalized cell grafts for stroke</i> | 164 |
| <i>Intravenous infusion of marrow stromal cells</i> | 165 |
| <i>Intravenous infusion of umbilical cord blood stem cells</i> | 165 |
| <i>Future of cell therapy for stroke</i> | 165 |
| Gene therapy of cerebrovascular diseases..... | 165 |
| <i>Gene transfer to cerebral blood vessels</i> | 166 |
| <i>NOS gene therapy for restenosis</i> | 167 |
| Gene therapy for cerebral ischemia..... | 167 |
| <i>Gene therapy of strokes with a genetic component</i> | 168 |
| Drug delivery to intracranial aneurysms..... | 169 |
| Drug delivery for vasospasm following subarachnoid hemorrhage..... | 169 |
| <i>Intrathecal tissue plasminogen activator</i> | 170 |
| <i>Gene therapy for vasospasm</i> | 171 |
| Drug delivery in multiple sclerosis | 172 |
| An electronic device for self injection of interferon beta-1a..... | 172 |
| Oral therapies for MS..... | 172 |
| Antisense and RNAi approaches to MS..... | 173 |
| Cell therapy for multiple sclerosis..... | 173 |
| <i>Hematopoietic stem cell transplantation for multiple sclerosis</i> | 173 |
| <i>Embryonic stem cells and neural precursor cells for MS</i> | 174 |
| Gene therapy for multiple sclerosis..... | 174 |
| Drug delivery in epilepsy | 175 |
| Routes of administration of antiepileptic drugs..... | 175 |
| <i>Controlled-release preparations of carbamazepine</i> | 175 |
| <i>Intravenous carbamazepine</i> | 176 |
| <i>Various methods of delivery of diazepam</i> | 176 |
| Methods of delivery of novel antiepileptic therapies..... | 176 |
| <i>Regulated activation of prodrugs</i> | 176 |
| <i>Use of neuronal membrane transporter</i> | 176 |
| <i>Delivery of the antiepileptic conopeptides to the brain</i> | 177 |
| <i>Nasal administration of AEDs</i> | 177 |
| <i>Intracerebral administration of AEDs</i> | 177 |
| The role of drug delivery in status epilepticus..... | 178 |
| Cell therapy of epilepsy..... | 179 |

| | |
|--|------------|
| Gene therapy for epilepsy | 179 |
| <i>Gene therapy for neuroprotection in epilepsy</i> | 180 |
| Concluding remarks on drug delivery in epilepsy | 180 |
| Drug delivery for pain | 181 |
| Intranasal delivery of analgesics | 182 |
| <i>Intranasal administration of morphine</i> | 182 |
| <i>Intranasal morphine derivatives</i> | 182 |
| <i>Intranasal fentanyl</i> | 183 |
| <i>Intranasal buprenorphine</i> | 184 |
| <i>Intranasal ketamine</i> | 184 |
| <i>Intranasal ketorolac</i> | 184 |
| Delivery of analgesics by inhalation | 185 |
| Spinal delivery of analgesics | 185 |
| <i>Epidural dexamethasone</i> | 187 |
| <i>Epidural morphine</i> | 187 |
| <i>Relief of pain by intrathecal ziconotide</i> | 188 |
| <i>Intrathecal neostigmine</i> | 189 |
| <i>Intrathecal prostaglandin antagonists</i> | 189 |
| <i>Intrathecal fadolmidine</i> | 189 |
| <i>Intrathecal siRNA for relief of neuropathic pain</i> | 189 |
| <i>Concluding remarks on intrathecal delivery of analgesic agents</i> | 189 |
| Intracerebroventricular drug delivery for pain | 190 |
| <i>Delivery of analgesics to the CNS across the BBB</i> | 190 |
| Drug delivery for migraine | 191 |
| Management of migraine | 191 |
| Novel drug delivery methods for migraine | 192 |
| <i>Nasal formulations for migraine</i> | 193 |
| <i>Sublingual spray for migraine</i> | 193 |
| <i>Needle-free drug delivery for migraine</i> | 193 |
| Relief of spasticity by intrathecal baclofen | 194 |
| Drug delivery for traumatic brain injury | 194 |
| Cell therapy of traumatic brain injury | 194 |
| <i>Gene therapy for traumatic brain injury</i> | 195 |
| Drug delivery for spinal cord injury | 195 |
| Administration of neurotrophic factors for spinal cord injury | 195 |
| Cell therapy for spinal cord injury | 196 |
| <i>Transplantation of glial cells for SCI</i> | 196 |
| <i>Fetal neural grafts for SCI</i> | 196 |
| <i>Embryonic stem cells for SCI</i> | 196 |
| <i>Schwann cell transplants for SCI</i> | 197 |
| <i>Olfactory glial cells for SCI</i> | 197 |
| <i>Marrow stromal cells for SCI</i> | 198 |
| <i>Intravenous injection of stem cells for spinal cord repair</i> | 198 |
| <i>Combinatorial approach for regeneration in SCI</i> | 198 |
| <i>Cell therapy of syringomyelia</i> | 198 |
| <i>Gene therapy of spinal cord injury</i> | 199 |
| Drug delivery in CNS infections | 199 |
| Drug delivery in neuroAIDS | 199 |
| Drug delivery for retinal disorders | 200 |
| <i>Age-related macular degeneration</i> | 200 |
| <i>TheraSight ocular brachytherapy system for wet AMD</i> | 201 |
| <i>Combretastatin A4P for myopic macular degeneration</i> | 201 |
| <i>Gene therapy for AMD</i> | 201 |
| <i>Anti-VEGF approach to AMD</i> | 202 |
| <i>Delivery of aptamers for treatment of AMD</i> | 202 |
| Stem cell therapy for retinitis pigmentosa | 203 |
| Proliferative retinopathies | 203 |
| Drug delivery for inner ear disorders | 203 |
| 6. Drug delivery for brain tumors | 205 |
| Introduction | 205 |
| Methods for evaluation of anticancer drug penetration into brain tumor | 205 |
| Innovative methods of drug delivery for glioblastoma multiforme | 205 |
| Delivery of anticancer drugs across the blood-brain barrier | 206 |
| Anticancer agents with increased penetration of BBB | 206 |
| BBB disruption | 207 |
| Nanoparticle-based targeted delivery of chemotherapy across the BBB | 208 |
| Tyrosine kinase inhibitor increases topotecan penetration into CNS | 209 |
| Bypassing the BBB by alternative methods of drug delivery | 210 |
| Intranasal perillyl alcohol | 210 |
| Intraarterial chemotherapy | 210 |

| | |
|--|------------|
| Enhancing tumor permeability to chemotherapy..... | 211 |
| PDE5 inhibitors for increasing BTB permeability | 211 |
| Local delivery of therapeutic agents into the brain | 211 |
| Biodegradable microspheres containing 5-FU..... | 211 |
| Carmustine biodegradable polymer implants | 211 |
| Fibrin glue implants containing anticancer drugs..... | 212 |
| Interstitial delivery of dexamethasone for reduction of peritumor edema..... | 212 |
| Magnetically controlled microspheres..... | 213 |
| Convection-enhanced delivery | 213 |
| CED for receptor-directed cytotoxin therapy | 213 |
| CED of topotecan | 213 |
| CED of a modified diphtheria toxin conjugated to transferrin | 214 |
| CED of nanoliposomal CPT-11..... | 214 |
| CED for delivery ¹³¹ I-chTNT-1/B Mab | 214 |
| Anticancer drug formulations for targeted delivery to brain tumors | 214 |
| Lipid-coated microbubbles as a delivery vehicle for taxol..... | 214 |
| Liposomes for drug delivery to brain tumors..... | 215 |
| MABs targeted to brain tumors | 215 |
| Multiple targeted drugs for brain tumors | 216 |
| Nanoparticles for targeted drug delivery in glioblastoma multiforme | 217 |
| Targeted antiangiogenic/apoptotic/cytotoxic therapies | 217 |
| Introduction of the chemotherapeutic agent into the CSF pathways..... | 218 |
| Intraventricular chemotherapy for meningeal cancer | 218 |
| Intrathecal chemotherapy | 219 |
| Photodynamic therapy for chemosensitization of brain tumors | 219 |
| Nanoparticles for photodynamic therapy of brain tumors..... | 220 |
| Innovative delivery of radiotherapy to brain tumors..... | 220 |
| GliaSite Radiation Therapy System..... | 220 |
| Boron neutron capture therapy for brain tumors | 220 |
| Cell therapy for glioblastoma multiforme..... | 221 |
| Mesenchymal stem cells to deliver treatment for gliomas | 221 |
| Gene therapy for glioblastoma multiforme..... | 221 |
| Antiangiogenic gene therapy | 222 |
| Anticancer drug delivery by genetically engineered MSCs..... | 223 |
| Intravenous gene delivery with nanoparticles into brain tumors | 223 |
| Ligand-directed delivery of dsRNA molecules targeted to EGFR | 223 |
| Neural stem cells for drug/gene delivery to brain tumors | 224 |
| Peptides targeted to glial tumor cells..... | 225 |
| RNAi gene therapy of brain cancer | 225 |
| Single-chain antibody-targeted adenoviral vectors | 225 |
| Targeting normal brain cells with an AAV vector encoding interferon- β | 226 |
| Treatment of medulloblastoma by suppressing genes in Shh pathway | 226 |
| Virus-mediated oncolytic therapy of brain cancer | 226 |
| <i>HIV-mediated Oncolysis.....</i> | 226 |
| <i>Autophagy by conditionally replicating adenoviruses.....</i> | 227 |
| <i>Reovirus-mediated Oncolysis.....</i> | 227 |
| <i>Measles virus-mediated oncolysis.....</i> | 228 |
| <i>Oncolytic virus targeted to brain tumor stem cells.....</i> | 228 |
| <i>Oncolysis with vesicular stomatitis virus.....</i> | 228 |
| <i>Future prospects of viral-mediated oncolysis</i> | 229 |
| Vaccination for glioblastoma multiforme | 229 |

| | |
|--|------------|
| 7. Markets for Drug Delivery in CNS Disorders..... | 231 |
| Introduction..... | 231 |
| Methods of calculation of CNS drug delivery markets..... | 231 |
| Markets for CNS drug delivery technologies..... | 231 |
| Drug delivery share in selected CNS markets..... | 232 |
| CNS share of drug delivery technologies | 232 |
| Geographical distribution of CNS drug delivery markets | 233 |
| Impact of improved drug delivery on CNS drug markets..... | 233 |
| Neurodegenerative disorders | 233 |
| <i>Alzheimer disease</i> | 233 |
| <i>Parkinson disease</i> | 234 |
| <i>Huntington disease.....</i> | 234 |
| <i>Amyotrophic lateral sclerosis</i> | 234 |
| Epilepsy | 235 |
| Migraine and other headaches | 235 |
| Stroke | 235 |
| Central nervous system trauma | 236 |
| Multiple sclerosis..... | 236 |
| Brain tumors | 236 |

| | |
|--|------------|
| Limitations of the current drug delivery technologies for CNS | 237 |
| Unmet needs in CNS drug delivery technologies | 237 |
| Future strategies for expanding CNS drug delivery markets | 238 |
| Education of neurologists | 238 |
| Demonstration of the advantages of the newer methods of delivery | 239 |
| Rescue of old products by novel drug delivery methods | 239 |
| Facilitation of the approval process of new drugs | 239 |
| 8. Companies | 241 |
| Introduction..... | 241 |
| Profiles | 241 |
| Collaborations..... | 317 |
| 9. References..... | 321 |

Tables

| | |
|---|-----|
| Table 1-1: Landmarks in the development of drug delivery to the CNS | 17 |
| Table 2-1: Proteins expressed at the neurovascular unit | 30 |
| Table 2-2: Transporters that control penetration of molecules across the BBB | 35 |
| Table 2-3: Enzymes that control the penetration of molecules across the BBB | 37 |
| Table 2-4: Factors that increase the permeability of the BBB..... | 42 |
| Table 2-5: Diseases that affect the BBB..... | 43 |
| Table 3-1: Various methods of drug delivery to the central nervous system | 57 |
| Table 3-2: Drugs available for intrathecal administration | 66 |
| Table 3-3: Strategies for drug delivery to the CNS across the BBB | 68 |
| Table 3-4: Specific inhibitors of P-glycoprotein in clinical development | 74 |
| Table 3-5: Molecules attached to Trojan horses injected intravenously for CNS effect..... | 79 |
| Table 3-6: Examples of controlled and sustained release drug delivery for CNS disorders..... | 91 |
| Table 3-7: Novel methods of delivery of drugs for CNS disorders | 92 |
| Table 3-8: Indications for the clinical applications of NTFs in neurologic disorders | 96 |
| Table 3-9: Methods for delivery of neurotrophic factors to the CNS | 97 |
| Table 4-1: Methods for delivering cell therapies in CNS disorders..... | 106 |
| Table 4-2: Classification of methods of gene therapy..... | 109 |
| Table 4-3: Methods of gene transfer as applied to neurologic disorders | 110 |
| Table 4-4: Potential indications for gene therapy of neurologic disorders | 116 |
| Table 4-5: Companies developing cell/gene therapies for CNS disorders | 117 |
| Table 4-6: Methods of antisense delivery as applied to the CNS | 119 |
| Table 5-1: Strategies for the treatment of Parkinson's disease | 127 |
| Table 5-2: Drug delivery systems for Parkinson's disease | 129 |
| Table 5-3: Types of cell used for investigative treatment of Parkinson's disease..... | 133 |
| Table 5-4: Status of cell therapies in development for Parkinson's disease | 134 |
| Table 5-5: Gene therapy techniques applicable to Parkinson disease | 139 |
| Table 5-6: Companies developing gene therapy for Parkinson's disease..... | 143 |
| Table 5-7: Classification of pharmacotherapy for Alzheimer disease | 144 |
| Table 5-8: Novel drug delivery methods for Alzheimer disease therapies | 145 |
| Table 5-9: Classification of neuroprotective agents for amyotrophic lateral sclerosis..... | 153 |
| Table 5-10: Methods of delivery of therapies in development for ALS | 153 |
| Table 5-11: Classification of treatments for stroke | 157 |
| Table 5-12: Treatments of stroke involving innovative drug delivery methods | 158 |
| Table 5-13: Drug delivery for prevention of carotid artery restenosis after angioplasty | 160 |
| Table 5-14: Gene transfer in animal models of carotid artery restenosis | 166 |
| Table 5-15: Neuroprotective gene transfer strategies in models of cerebral ischemia..... | 167 |
| Table 5-16: Gene Therapy for reducing cerebral infarction in animal stroke models..... | 168 |
| Table 5-17: Pharmacological agents for treatment of cerebral vasospasm | 170 |
| Table 5-18: Gene therapy strategies for vasospasm | 171 |
| Table 5-19: A classification of drug delivery methods used in management of pain | 181 |
| Table 5-20: Spinal administration of drugs for pain | 186 |
| Table 5-21: Investigational drugs for pain administered by intrathecal route | 186 |
| Table 5-22: Current management of migraine | 191 |
| Table 5-23: Novel drug delivery methods for migraine..... | 192 |
| Table 6-1: Innovative methods of drug delivery for glioblastoma multiforme | 205 |
| Table 6-2: Strategies for gene therapy of malignant brain tumors..... | 221 |
| Table 7-1: Share of drug delivery technologies in selected CNS markets: 2011-2021 | 232 |
| Table 7-2: CNS market share of drug delivery technologies 2011-2021 | 232 |
| Table 7-3: Value of CNS drug delivery in the major world markets from 2011-2021 | 233 |
| Table 7-4: Limitations of the current drug delivery technologies for CNS..... | 237 |
| Table 8-1: Collaborations of companies in CNS drug delivery..... | 317 |

Figures

| | |
|---|-----|
| Figure 1-1: Interaction of neurotransmitters with receptors | 20 |
| Figure 2-1: The neurovascular unit | 29 |
| Figure 2-2: Various forms of passage of substances across the blood brain barrier | 34 |
| Figure 3-1: Routes of drug delivery to the brain..... | 58 |
| Figure 3-2: Use of receptor-mediated transcytosis to cross the BBB | 80 |
| Figure 5-1: Oral versus transdermal administration of a drug in Parkinson's disease | 132 |
| Figure 5-2: Effect of tyrosine hydroxylase gene delivery on dopamine levels | 140 |
| Figure 6-1: A concept of targeted drug delivery to GBM across the BBB | 208 |
| Figure 7-1: Unmet needs in the CNS drug delivery technologies | 238 |